CASE PRESENTATION: A 39-year-old female with high-risk HR-positive, HER2-negative early breast cancer commenced adjuvant abemaciclib with letrozole following completion of chemotherapy and radiotherapy. Here, ERBB2 is linked to breast carcinoma.